Archives

Marcia P. Belvin, Ph.D.

Dr. Belvin joined CytomX in 2018. Prior to this, Dr. Belvin held roles of increasing responsibility at Genentech where, over 13 years, she led multiple preclinical pipeline teams and oversaw programs in cancer signaling, cancer metabolism, and cancer immunology. Dr. Belvin began her career at Exelixis where she managed teams responsible for preclinical pipeline discovery within the oncology and inflammation portfolios. Dr. Belvin received her B.A. degree from Harvard University and her Ph.D. from the University of California, Berkeley. Dr. Belvin also trained at the Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory.

Learn More

Carlos Campoy

Mr. Campoy brings over 30 years of financial and leadership experience, the majority from publicly held companies within the healthcare and biopharmaceutical sectors. Most recently, Mr. Campoy held the position of chief financial officer at Alder BioPharmaceuticals, which was acquired in October 2019 by Lundbeck A/S, where he led the finance organization and readied the company for commercial launch of its lead program, eptinezumab, a recently approved treatment for the prevention of migraine.  Prior to Alder, Mr. Campoy held the role of vice president of finance, international at Allergan plc. Prior to joining Allergan, over the course of an 18-year tenure at Eli Lilly and Company, Mr. Campoy held senior financial leadership positions including most recently as chief financial officer of Eli Lilly Japan K.K.  Mr. Campoy received his M.B.A. in Finance and Decision Information Systems from Indiana University and his B.S. in Management from Faculdade C.C. Administracao de Tupa, in São Paulo, Brazil. Mr. Campoy holds a Certified Management Accountant (CMA) designation.

Learn More

Alison L. Hannah, M.D.

Alison L. Hannah, M.D. joined as senior vice president and chief medical officer. Dr. Hannah brings 30 years of experience in the development of investigational cancer therapies having most recently served as a consultant to nearly 30 pharmaceutical and biotechnology companies. In this capacity, Dr. Hannah has successfully filed over 40 regulatory applications for First-in-Human clinical testing, and has played significant roles in the broad marketing approval of 8 therapeutics (talazoparib, enzalutamide, defibrotide, carfilzomib, sunitinib, toceranib, irinotecan and filgrastim) including extensive experience interacting with global health and regulatory authorities. Earlier in her career, Dr. Hannah held the role of Senior Medical Director at SUGEN, Inc. (acquired by Pharmacia & Upjohn, now Pfizer) where she had oversight of clinical development, clinical operations, and pharmacovigilance. At SUGEN, she specialized in the development of tyrosine kinase inhibitors, including sunitinib (SUTENT) for kidney cancer. Dr. Hannah began her career at Quintiles, a global contract research organization, where she specialized in overseeing early to registrational-stage oncology clinical trials. Dr. Hannah currently serves on the board of NeoGenomics, a publicly traded cancer diagnostic company. Dr. Hannah received her B.A in biochemistry and immunology from Harvard University and her M.D. from the University of Saint Andrews.

Learn More

Nick Galli, J.D.

Nick Galli, J.D. joined CytomX in February 2019. Mr. Galli most recently held the position of vice president, business development at Denali Therapeutics where he led the execution of more than twenty collaborations, including strategic partnerships with Sanofi-Genzyme, Takeda, Genentech and F-star. Prior to Denali, Mr. Galli was senior director, transactions at Johnson & Johnson Innovation Center.  Prior to this, Mr. Galli held roles of increasing responsibility at Genentech within the business development and transactional law groups. Mr. Galli began his career as a corporate attorney at the law offices of Skadden, Arps, Slate, Meagher & Flom and practiced in the technology transactions group at Wilson Sonsini Goodrich & Rosati. Mr. Galli received his B.A. degree from Princeton University and his J.D. from the Georgetown University Law Center.

 

Learn More

Lloyd A. Rowland, Jr., J.D.

Lloyd Rowland, Jr., joined CytomX in May 2018 as senior vice president, general counsel, secretary and chief compliance officer. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience to CytomX. Most recently, Mr. Rowland held the position of senior vice president, general counsel and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to this, Mr. Rowland, over a twelve-year career at Amylin Pharmaceuticals, held various roles, most recently as vice president and chief compliance officer and formerly, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.

Learn More

Alison Joly, Ph.D.

Alison Joly, Ph.D., has worked in the biotechnology sector for more than 20 years serving in multiple roles involved in oncology drug discovery, development and commercialization. Prior to joining CytomX in April 2016 as senior vice president, program and alliance management, Dr. Joly spent 14 years at Exelixis, most recently serving as vice president of program management for oncology. She oversaw multiple external partnerships relating to early and mid-stage development assets and played a critical role in the development, approval and launch of COMETRIQTM (cabozantinib) for locally advanced metastatic medullary thyroid carcinoma. Prior to Exelixis, Dr. Joly served as a scientist at Scios and CV Therapeutics. Dr. Joly holds a bachelor of science and a doctorate in biochemistry from The University of Liverpool, U.K., and completed her postdoctoral research at University of Florida and University of California, Los Angeles.

Learn More

Sridhar Viswanathan, Ph.D.

Sridhar Viswanathan, Ph.D., is the senior vice president of process sciences and manufacturing operations. Dr. Viswanathan previously served as vice president of process development and manufacturing operations for Perseid Therapeutics, a joint venture between Maxygen and Astellas that was subsequently acquired by Astellas. He was responsible for all internal process development and external manufacturing operations at contract manufacturing organizations for advancing CTLA4-Ig Fc fusion products for autoimmune disease and organ transplant rejection. Before joining Perseid, Dr. Viswanathan spent several years at Maxygen directing process development and clinical manufacturing for next-generation biologics programs, including PEGylated interferon alpha, PEG-G-CSF and FVIIa. Prior to this, he held positions at Coulter Pharmaceutical, Bayer Corporation and Genentech. He received his doctorate in biochemistry from the University of Mississippi Medical Center and completed postdoctoral training at Rockefeller University and Stanford University.

Learn More

Danielle Olander

Danielle T. Olander joined CytomX in 2014, and serves as senior vice president of talent and systems development.  She is accountable for optimizing talent, bringing organizational systems to life, and helping the organization to achieve our mission, vision, and values.  As an industry innovator, she has developed a strategic plan that includes the creation of a system for aligning our corporate goals with our business strategy that has resulted in significant growth, scalability, and sustainability.  Danielle leads the following functions for the organization: human resources, information technology, facilities, and administration.  Prior to CytomX, Danielle held leadership positions at Portola Pharmaceuticals, SuperGen (now Astex Pharmaceuticals), SUGEN (acquired by Pfizer) and Kinetic Search.  She received her B.S. in human resource management from Colorado Technical University.

Learn More

Amy C. Peterson, M.D.

Amy Peterson, M.D. joined CytomX in October 2019 as executive vice president and chief development officer. Prior to joining CytomX, Dr. Peterson was chief medical officer of immuno-oncology at BeiGene, Ltd. where she created and led a global oncology development organization with direct medical oversight and accountability of 7 clinical assets in over thirty global trials in all phases of development in solid tumor indications. Prior to BeiGene, Dr. Peterson was vice president of clinical development at Medivation where she was primarily responsible for the development of enzalutamide (XTANDI®) and talazoparib (TALZENNA®) in breast cancer. Previously, Dr. Peterson served as associate group medical director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology. Prior to joining Genentech, Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski. She currently serves on the board of The American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation. Dr. Peterson received her M.D. from Thomas Jefferson University and completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. Dr. Peterson received her B.A. degree from Wesleyan University.

Learn More

W. Michael Kavanaugh, M.D.

Michael Kavanaugh, M.D. joined CytomX in January 2015 as senior vice president, chief scientific officer and head of research and early development. Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company’s therapeutic pipeline. Before Five Prime, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis in 2006 as part of the company’s acquisition of the Chiron Corporation, where he was vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of medicine at UCSF.

Learn More